AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30298593
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents (DES-II)
Trial: 30299230
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous (iv) alteplase (0.6 mg/kg body weight)
Trial: 30302599
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily with mFOLFOX-6 + bevacizumab
Trial: 30302599
Drug: Everolimus 7.5
RxNorm normalized name: everolimus 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 7.5 mg daily with mFOLFOX-6 + bevacizumab (recommended phase II dose)
Trial: 30305055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of obatoclax and TRAIL
Trial: 30305103
Drug: Online Emotion
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online Emotion Regulation Individual Therapy for Adolescents (ERITA)
Trial: 30305449
Drug: Intrathecal rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intrathecal rituximab (25 mg with a 1-week interval)
Trial: 30305961
Drug: Nitrate-rich fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich fruit and vegetable liquid supplement (FVS, AMPED NOx, Isagenix International LLC)
Trial: 30307350
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 20% intravenous lipid emulsion
Trial: 30309472
Drug: Home fetal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home fetal heart rate monitoring (FHRM) twice daily with a Doppler monitor and weekly or biweekly fetal echocardiograms.
Trial: 30309758
Drug: Obinutuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles)
Trial: 30309993
Drug: Flavoured cigar
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flavoured cigar (apple, cream, original, wine)
Trial: 30310267
Drug: Ranibizumab with
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab with photodynamic therapy (PDT group)
Trial: 30311073
Drug: HUMAN (manually-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HUMAN (manually-adapted target controlled infusion protocol)
Trial: 30312717
Drug: Salvage low-dose-rate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage low-dose-rate (LDR) brachytherapy
Trial: 30314417
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment with additional one-on-one self-efficacy enhancement sessions
Trial: 30317671
Drug: ixekizumab 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixekizumab 160 mg at Week 0, 80 mg every 2 weeks through Week 12, and 80 mg every 4 weeks thereafter up to Week 244
Trial: 30318513
Drug: ARQ 761
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ 761 (β-lapachone analogue) at a maximum tolerated dose of 390 mg/m, administered on three schedules (weekly, every other week, 2/3 weeks)
Trial: 30318646
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) dose
Trial: 30319400
Drug: Metronomic four-drug
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic four-drug regimen
Trial: 30319729
Drug: Nonthermal Pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonthermal Pulsed Ultrasound Treatment
Trial: 30320410
Drug: Factors influencing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors influencing implant decision
Trial: 30321257
Drug: Cox proportional
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cox proportional hazards models adjusted for various factors including age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins.
Trial: 30321314
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of both NNRTI/nucleoside reverse transcriptase inhibitor PDR
Trial: 30323658
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard fractionated radiotherapy): 50.4 Gy in 28 fractions plus a sequential electron boost of 10 Gy in 4 fractions.
Trial: 30323863
Drug: Sublingual allergen
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen immunotherapy (SLIT) with house dust mite (HDM) extract
Trial: 30323946
Drug: Daily activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activity feedback via smartwatch over a 9-hour period
Trial: 31726452
Drug: BoNT-A injection
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT-A injection
Trial: 30324586
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg bid) with Tamoxifen (60 mg loading dose qd days 10-13, 20 mg qd days 14-26)
Trial: 30324586
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg bid) with Anastrozole (1 mg qd days 10-19)
Trial: 30324586
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg bid) with Letrozole (2.5 mg qd days 10-38)
Trial: 30324586
Drug: Olaparib monotherapy
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib monotherapy (300 mg bid continuously)
Trial: 30325534
Drug: Ixekizumab (160-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, then 80 mg every 4 weeks until Week 52)
Trial: 30325534
Drug: Treatment Withdrawal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Withdrawal Period (Weeks 52 to 100)
Trial: 30325534
Drug: Treatment Withdrawal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Withdrawal Period
Trial: 30325779
Drug: HIV-infected individuals
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected individuals with reduced subcutaneous adipose tissue (SAT)
Trial: 30326301
Drug: Pan-enteric capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pan-enteric capsule endoscopy (PCE)
Trial: 30326968
Drug: Centralized clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centralized clinical data and biological samples collection
Trial: 30326968
Drug: Biological samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biological samples (blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials, fine needle biopsy of metastases, and surgically resected tissue)
Trial: 30327612
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of energy
Trial: 30327731
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection with 40 mg of Methylprednisolone Acetate and 2 ml of Lidocaine
Trial: 30328062
Drug: Manual preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual preparation of fecal microbiota
Trial: 30328062
Drug: Automatic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic preparation of fecal microbiota
Trial: 30328739
Drug: Potential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential treatment for UI
Trial: 30333050
Drug: Oral debriefing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral debriefing
Trial: 30333050
Drug: Oral debriefing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral debriefing assisted by video
Trial: 30333052
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and PAP (Physical Activity on Prescription)
Trial: 30333224
Drug: Cerdulatinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerdulatinib (oral administration, dose-escalation, once-daily or twice-daily schedules)
Trial: 30333224
Drug: Cerdulatinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerdulatinib (oral administration)
Trial: 30334521
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests (TST and IGRAs)
Trial: 30334527
Drug: Contrast volume
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast volume quartile Q1 (≤100 ml)
Trial: 30334527
Drug: Contrast volume
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast volume quartile Q2 (101-140 ml)
Trial: 30334527
Drug: Contrast volume
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast volume quartile Q3 (141-200 ml)
Trial: 30334527
Drug: Contrast volume
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast volume quartile Q4 (>200 ml)
Trial: 30334909
Drug: docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 100 mg/m² (n=84)
Trial: 30334909
Drug: doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 75 mg/m² (n=97)
Trial: 30335559
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler)
Trial: 31863283
Drug: Sequential afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential afatinib and osimertinib
Trial: 30336828
Drug: Therapy initiation
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy initiation
Trial: 30337358
Drug: Sotatercept (≥0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (≥0.1 mg/kg) in non-transfusion-dependent β-thalassemia
Trial: 30337358
Drug: Sotatercept (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (1.0 mg/kg) in transfusion-dependent β-thalassemia
Trial: 30338261
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Ibuprofen
Trial: 30339892
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tramadol and paracetamol
Trial: 30339892
Drug: Standardised take-home
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standardised take-home analgesic and PONV strategies
Trial: 30340199
Drug: Ruxolitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (5 mg, 10 mg, and 15 mg twice daily)
Trial: 30340532
Drug: Intracoronary morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary morphine (1 mg)
Trial: 30341043
Drug: Weekly motivational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly motivational emails during the treatment phase
Trial: 30341051
Drug: Personal coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal coaching intervention (monthly calls with limited app components)
Trial: 30341664
Drug: Patient insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient insulin injection technique (IT)
Trial: 30341664
Drug: Nurse insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse insulin injection technique (IT)
Trial: 30341664
Drug: Patient insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient insulin injection technique (IT) score
Trial: 30341681
Drug: Salt excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt excretion measurement
Trial: 30342919
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of D7-cholesterol
Trial: 30343026
Drug: Daily co-formulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP
Trial: 30343254
Drug: FOLFIRINOX induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX induction therapy
Trial: 30343526
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (defined as serum 25(OH)D < 10 ng/mL) in ENKTL patients
Trial: 30343614
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for three cycles before radical cystectomy (RC)
Trial: 30343896
Drug: PLB-1001 (MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB-1001 (MET kinase inhibitor)
Trial: 30344036
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use disorder diagnosis
Trial: 30344063
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Statins (both drugs)
Trial: 30344179
Drug: Geriatric co-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric co-management with proactive consultation for low-risk patients, co-management by geriatric nurse for high-risk patients, and additional medication review for patients with acute geriatric problems.
Trial: 30345376
Drug: Concurrent systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent systemic disease
Trial: 30346260
Drug: Endovascular stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular stroke treatment
Trial: 30348127
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (docetaxel and cyclophosphamide, TC)
Trial: 30348216
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Trial: 30348216
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus Pazopanib (800 mg/day)
Trial: 30348537
Drug: DPYD genotype-guided
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD genotype-guided dosing (initial dose reduction of 25% for c.2846A>T and c.1236G>A carriers, 50% for DPYD*2A and c.1679T>G carriers)
Trial: 30348537
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (full dose fluoropyrimidine-based therapy)
Trial: 30348537
Drug: Historical cohort
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical cohort (full dose fluoropyrimidine-based therapy)
Trial: 30348638
Drug: SHR-1210 (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) combination therapy
Trial: 30350179
Drug: Trifluridine/tipiracil (FTD/TPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (FTD/TPI) 35 mg/m² during a 28-day treatment cycle
Trial: 30351341
Drug: Hsp90 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hsp90 inhibitor luminespib (AUY922)
Trial: 30352440
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) on
Trial: 30352440
Drug: Cochlear Implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implant (CI) off
Trial: 30352576
Drug: HYP-RT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYP-RT with concomitant CDDP (4 weekly cycles of 35 mg/m2)
Trial: 30352608
Drug: FDG and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy
Trial: 30352608
Drug: Concomitant chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemo-radiotherapy (reference treatment)
Trial: 30352714
Drug: Postdischarge opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge opioid prescription (median 225mg OMEQ)
Trial: 30352941
Drug: Dalantercept (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalantercept (0.6 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Trial: 30352941
Drug: Dalantercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalantercept (0.4 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Trial: 30353044
Drug: Olaparib (Lynparza™)
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib (Lynparza™) maintenance monotherapy
Trial: 30353806
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) treatment for 4 months
Trial: 30353806
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PAP treatment)
Trial: 30353806
Drug: PAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP treatment adherence in participants without obesity
Trial: 30353817
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain in NCP group
Trial: 30354636
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon treatment
Trial: 30354645
Drug: Drug-Coated Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloon
Trial: 30354737
Drug: Appropriate secondary
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate secondary prevention treatment at discharge (dual antiplatelet therapy and moderate/high dose statins, new-P2Y12 inhibitors, ACE inhibitors/ARBs, beta-blockers as indicated)
Trial: 30354737
Drug: Evidence-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatments at discharge
Trial: 30355158
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299v (20 billion CFU) once daily for 6 weeks
Trial: 30355158
Drug: Vancomycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (250 mg QID for 10 days)
Trial: 30355795
Drug: Intravenous dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextrose without any parenteral nutrition (PN)
Trial: 30345376
Drug: Evidence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence of concurrent systemic disease
Trial: 30358179
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of nelfinavir during the third trimester
Trial: 30358468
Drug: Eligibility for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligibility for UshStat® gene therapy
Trial: 30359447
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 2g of azithromycin
Trial: 30359909
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg/day) - Cohort 1 (C1)
Trial: 30359909
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg/day) - Cohort 2 (C2)
Trial: 30361262
Drug: Venetoclax (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400, 800, or 1200 mg daily) combined with decitabine (20 mg/m²)
Trial: 30361262
Drug: Venetoclax (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400, 800, or 1200 mg daily) combined with azacitidine
Trial: 30361296
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists before intervention